

Support for amended Claim 13 can be found, for example, on page 1, lines 14-17, on page 5, line 35 - page 6, line 7, and in Figures 2 and 3.

Support for amended Claim 14 can be found, for example, on page 2, lines 25-32, on page 5, line 35 - page 6, line 7, and in Figures 2 and 3.

Support for amended Claim 15 can be found, for example, on page 1, lines 14-17, on page 5, line 35 - page 6, line 7, and in Figures 2 and 3.

Support for amended Claim 16 can be found, for example, on page 2, lines 25-32, on page 5, line 35 - page 6, line 7, and in Figures 2 and 3.

Support for amended Claim 17 can be found, for example, on page 2, lines 25-32, on page 5, line 35 - page 6, line 7, and in Figures 2 and 3.

No new matter has been added by the above amendments and the Examiner is respectfully requested to enter them.

CONCLUSION


If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney at (831) 648-3090.

PATENT

ATTORNEY DOCKET NO. CABE.001.01US

Respectfully submitted,

Dated: July 10, 2003



Barbara Rae-Venter, Ph.D.
Reg. No. 32,750

Rae-Venter Law Group, P.C.
PO Box 1898
Monterey, CA 93942-1898
Phone: (831) 648-3090
Facsimile: (831) 242-0137

BRV/mnb

PATENT

ATTORNEY DOCKET NO. CABE.001.01US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Johannes J. Geuze *et al.*

) Examiner: DeCloux, Amy

Serial No.: 09/011,167

) Art Unit: 1644

Filed: June 2, 2003

Title: CELL DERIVED ANTIGEN PRESENTING
VESICLES

) MARKED UP COPY OF CLAIMS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The Examiner is respectfully requested to make the amendments shown below. A Clean Copy of the text of the claims following entry of the amendments is attached hereto.

IN THE CLAIMS:

13. (Amended) An antigen presenting vesicle free from its natural surroundings, said vesicle comprising:

CERTIFICATE OF FIRST CLASS MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

July 10, 2003
(Date of Deposit)


(Signature)

Carrie Bucher
(Printed Name)

a membrane, a major histocompatibility complex (MHC) Class [I] II protein, and one or more at least partially processed antigens bound to said MHC [class I] Class II protein, [and] wherein said antigen presenting vesicle is obtainable from a B lymphocyte.

14. (Amended) The antigen presenting vesicle according to Claim 13, wherein said vesicle is obtained by the step of recovering a 70,000 x g pellet obtained by differential centrifugation of membrane-containing fractions of cell culture media or lysates of B lymphocytes containing said MHC Class [I] II protein.

15. (Amended) An antigen presenting vesicle free from its natural surroundings, said vesicle comprising:

a membrane, a major histocompatibility complex (MHC) Class [I] II protein, and one or more at least partially processed antigens bound to said MHC Class [I] II protein, [and] wherein said antigen presenting vesicle is derived from culture media of B-lymphocytes containing said MHC Class [I] II protein.

16. (Amended) An antigen presenting vesicle free from its natural surroundings, said vesicle comprising:

a membrane, a major histocompatibility complex (MHC) Class [I] II protein, and one or more at least partially processed antigens bound to said MHC Class [I] II protein, wherein said antigen presenting vesicle is obtained by the step of recovering a 70,000 x g pellet obtained by differential centrifugation of membrane-containing fractions of cell culture media or lysates of B-lymphocytes containing said MHC Class [I] II protein.

17. (Amended) An antigen presenting vesicle free from its natural surroundings, said vesicle comprising:

PATENT


ATTORNEY DOCKET NO. CABE.001.01US

a membrane, [a] major histocompatibility complex (MHC) Class I and Class II proteins, and one or more at least partially processed antigens bound to said MHC Class I and Class II proteins, wherein said antigen presenting vesicle is obtained by [the step of recovering a 70,000 x g pellet obtained by] differential centrifugation of membrane-containing fractions of cell culture media or lysates of B-lymphocytes containing said MHC Class I and Class II proteins.

Respectfully submitted,

Dated:

July 10, 2005



Barbara Rae-Venter, Ph.D.

Reg. No. 32,750

Rae-Venter Law Group, P.C.
PO Box 1898
Monterey, CA 93942-1898
Phone: (831) 648-3090
Facsimile: (831) 242-0137

BRV/mnb